Mostrar el registro sencillo del ítem

dc.contributor.author
Maiorana, Facundo Nicolás  
dc.contributor.author
Neschuk, Magali  
dc.contributor.author
Caronia, María Virginia  
dc.contributor.author
Elizondo, Karina  
dc.contributor.author
Schneider, Adolfo  
dc.contributor.author
Veron, Georgina  
dc.contributor.author
Zapata, Pedro Dario  
dc.contributor.author
Barreyro, Fernando Javier  
dc.date.available
2024-10-04T12:20:04Z  
dc.date.issued
2024-08  
dc.identifier.citation
Maiorana, Facundo Nicolás; Neschuk, Magali; Caronia, María Virginia; Elizondo, Karina; Schneider, Adolfo; et al.; Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease; Elsevier; Annals of Hepatology; 29; 6; 8-2024; 1-10  
dc.identifier.issn
2659-5982  
dc.identifier.uri
http://hdl.handle.net/11336/245481  
dc.description.abstract
Introduction and Objectives: Recent studies have suggested an association between H. pylori and metabolic dysfunction associated steatotic liver disease (MASLD). We aim to evaluate the association of H. pylori virulence genes with non-invasive markers of liver injury and fibrosis in MASLD subjects.Patients and Methods: A total of 362 dyspeptic patients who underwent gastroscopy were selected. Biochemical, clinical parameters, ultrasound, FIB-4 score, liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE), gastric biopsies, and H. pylori virulence genes (cagA, vacA) were evaluated.Results: A cohort comprised of 61 % women and 39 % men with a median age of 52 (40−60) years. MASLD was observed in 42 %, and H. pylori-positive in 45 %. No differences were observed regarding H. pylori status at comorbid metabolic conditions. In MASLD cohort, H. pylori-positive was associated with higher AST, ALT, FIB-4 and LSM. Indeed, carriers of cagA/vacA-s1/m1-positive allelic combination were associated with higher AST, ALT, FIB-4 and LSM but not cagA/vacA-s1/m1-negative. The OR for high-risk of significant/advanced- fibrosis by VCTE (8 kPa) with H. pylori-positive was 2.56 (95 % CI, 1.2−5.75) and for cagA/vacA-s1/-m1-positive allelic carriers was 4.01 (95 % CI, 1.38−11.56), but non-significant association in cagA/vacA-s1/-m1-negative. After adjusting for age, gender, diabetes, BMI and hypertension the OR for VCTE 8 kPa with H. pylori-positive was 2.43 (95 % CI, 1.88−12.44), and cagA/vacA-s1/m1-positive allelic carriers was 4.06 (95 % CI, 1.22−14.49).Conclusions: In our cohort of FD patients with MASLD, H. pylori was associated with non-invasive markers of liver injury and fibrosis. Carriers of cagA/vacA-s1/m1-positive allelic combination showed an independent risk of significant/advanced fibrosis by VCTE.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Elsevier  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/  
dc.subject
HELICOBACTER PILORY  
dc.subject
POLIMORPHISMS  
dc.subject
LIVER DISEASE  
dc.subject.classification
Tecnologías que involucran la identificación de ADN, proteínas y enzimas, y cómo influyen en el conjunto de enfermedades y mantenimiento del bienestar  
dc.subject.classification
Biotecnología de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2024-10-01T12:10:28Z  
dc.journal.volume
29  
dc.journal.number
6  
dc.journal.pagination
1-10  
dc.journal.pais
Países Bajos  
dc.description.fil
Fil: Maiorana, Facundo Nicolás. Universidad Nacional de Misiones. Facultad de Ciencias Exactas Químicas y Naturales. Departamento de Bioquímica Clínica. Laboratorio de Biotecnología Molecular; Argentina  
dc.description.fil
Fil: Neschuk, Magali. Universidad Nacional de Misiones. Facultad de Ciencias Exactas Químicas y Naturales. Departamento de Bioquímica Clínica. Laboratorio de Biotecnología Molecular; Argentina  
dc.description.fil
Fil: Caronia, María Virginia. Universidad Nacional de Misiones. Facultad de Ciencias Exactas Químicas y Naturales. Departamento de Bioquímica Clínica. Laboratorio de Biotecnología Molecular; Argentina  
dc.description.fil
Fil: Elizondo, Karina. Instituto Universidad de la Fundación "Héctor Barceló"; Argentina  
dc.description.fil
Fil: Schneider, Adolfo. Instituto Universidad de la Fundación "Héctor Barceló"; Argentina  
dc.description.fil
Fil: Veron, Georgina. Instituto Universidad de la Fundación "Héctor Barceló"; Argentina  
dc.description.fil
Fil: Zapata, Pedro Dario. Universidad Nacional de Misiones. Facultad de Ciencias Exactas Químicas y Naturales. Departamento de Bioquímica Clínica. Laboratorio de Biotecnología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina  
dc.description.fil
Fil: Barreyro, Fernando Javier. Universidad Nacional de Misiones. Facultad de Ciencias Exactas Químicas y Naturales. Departamento de Bioquímica Clínica. Laboratorio de Biotecnología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina  
dc.journal.title
Annals of Hepatology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S1665268124003351  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.aohep.2024.101541